Xiangyang Bao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiangyang Bao has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Lian Duan
Chinese PLA General Hospital
18 shared publications Gan Gao
Medical School of Chinese PLA, Beijing, China
10 shared publicationsQian Zhang
Senior Department of Neurosurgery The Fifth Medical Center of Chinese PLA General Hospital Beijing China
10 shared publicationsQian-Nan Wang
Department of Neurosurgery, the Eighth Medical Centre, Chinese PLA General Hospital, Beijing, China
9 shared publicationsDan Yu
Senior Department of Neurosurgery The Fifth Medical Center of Chinese PLA General Hospital Beijing China
8 shared publicationsJingjie Li
Medical School of Chinese PLA, Beijing, China
7 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (15)
Integrated Serum Multiomics Reveal Subtype‐Specific Immune Dysregulation and Sex‐Dimorphic Pathophysiology in Moyamoya Disease
Background: Moyamoya disease (MMD) is a rare cerebrovascular disorder with unknown pathogenesis, partly due to limited access to human cerebral vascular tissue and suitable animal models. Using a large biobank of frozen serum samples, this study aimed to explore molecular signatures of ischemic and hemorrhagic MMD. Methods: Serum from 30 patients with MMD (18 ischemic, 12 hemorrhagic) and 30 matched healthy controls underwent proteomic and metabolomic profiling. Data were analyzed for differential expression, pathway enrichment, and protein–metabolite networks, with adjustment for age, sex, and body mass index. Results: In a separate large Chinese cohort (n=6167), female patients had a higher proportion of hemorrhagic MMD (19.9% versus 16.9%) and a higher prevalence of anterior choroidal artery dilation (15.1% versus 13.2%) than male patients (both P <0.05). At the molecular level, ischemic MMD showed complement C4‐B deficiency and disrupted natural killer cell cytotoxicity; both subtypes shared immunoglobulin perturbations (eg, decreased heavy‐chain variable regions). Sex‐specific alterations included anti–folate‐binding protein, serum amyloid A2, glycolithocholic acid, and estradiol. All omics data are publicly accessible. Conclusions: Integrated serum multiomics defines distinct immune‐related signatures for ischemic and hemorrhagic MMD and reveals sex‐dimorphic molecular pathways. These findings, together with clinical sex differences in disease subtype and vascular anatomy, provide a framework for personalized, sex‐aware management of MMD.
- 4 August 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (15)
Open AccessIntegrated Serum Multiomics Reveal Subtype‐Specific Immune Dysregulation and Sex‐Dimorphic Pathophysiology in Moyamoya Disease
Background: Moyamoya disease (MMD) is a rare cerebrovascular disorder with unknown pathogenesis, partly due to limited access to human cerebral vascular tissue and suitable animal models. Using a large biobank of frozen serum samples, this study aimed to explore molecular signatures of ischemic and hemorrhagic MMD. Methods: Serum from 30 patients with MMD (18 ischemic, 12 hemorrhagic) and 30 matched healthy controls underwent proteomic and metabolomic profiling. Data were analyzed for differential expression, pathway enrichment, and protein–metabolite networks, with adjustment for age, sex, and body mass index. Results: In a separate large Chinese cohort (n=6167), female patients had a higher proportion of hemorrhagic MMD (19.9% versus 16.9%) and a higher prevalence of anterior choroidal artery dilation (15.1% versus 13.2%) than male patients (both P <0.05). At the molecular level, ischemic MMD showed complement C4‐B deficiency and disrupted natural killer cell cytotoxicity; both subtypes shared immunoglobulin perturbations (eg, decreased heavy‐chain variable regions). Sex‐specific alterations included anti–folate‐binding protein, serum amyloid A2, glycolithocholic acid, and estradiol. All omics data are publicly accessible. Conclusions: Integrated serum multiomics defines distinct immune‐related signatures for ischemic and hemorrhagic MMD and reveals sex‐dimorphic molecular pathways. These findings, together with clinical sex differences in disease subtype and vascular anatomy, provide a framework for personalized, sex‐aware management of MMD.
- Open Access
- 9 May 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (5) , e70917
Optimal Surgical Timing and Outcome Prediction in Hemorrhagic Moyamoya Disease: A Retrospective Cohort Study
Objective: To develop and validate a prognostic nomogram incorporating optimal surgical timing thresholds for predicting long‐term outcomes in adult hemorrhagic moyamoya disease (MMD) patients undergoing encephaloduroarteriosynangiosis (EDAS). Methods: We conducted a retrospective cohort study of 256 consecutive adults with hemorrhagic MMD treated with EDAS (2013–2017) at a tertiary neurosurgical center. Using least absolute shrinkage and selection operator (LASSO) regression with 10‐fold cross‐validation, we identified key predictors for nomogram development. The model's performance was rigorously evaluated through discrimination (C‐index, AUC‐ROC), calibration, and decision curve analysis (DCA) in both training (70%) and validation (30%) cohorts. Results: Our hemorrhage‐specific nomogram incorporated five independent predictors: (1) age at initial hemorrhage, (2) surgical timing (optimal 3–6 month window post‐ictus), (3) preoperative functional status (modified Rankin Scale), (4) perioperative complications, and (5) recurrent hemorrhage. The model demonstrated excellent discrimination (C‐index: 0.889 training, 0.819 validation) and calibration. DCA confirmed superior clinical utility across 15%–80% probability thresholds compared to conventional approaches. Restricted cubic spline analysis validated the non‐linear relationship between surgical timing and outcomes. Conclusions: This study provides the first validated clinical decision tool for adult hemorrhagic MMD, establishing 3–6 months post‐hemorrhage as the optimal surgical window for EDAS. The nomogram's robust performance metrics and RCS‐validated temporal risk stratification offer neurosurgeons an evidence‐based approach to optimize revascularization timing and improve functional outcomes.
- 9 May 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (5) , e70917
Open AccessOptimal Surgical Timing and Outcome Prediction in Hemorrhagic Moyamoya Disease: A Retrospective Cohort Study
Objective: To develop and validate a prognostic nomogram incorporating optimal surgical timing thresholds for predicting long‐term outcomes in adult hemorrhagic moyamoya disease (MMD) patients undergoing encephaloduroarteriosynangiosis (EDAS). Methods: We conducted a retrospective cohort study of 256 consecutive adults with hemorrhagic MMD treated with EDAS (2013–2017) at a tertiary neurosurgical center. Using least absolute shrinkage and selection operator (LASSO) regression with 10‐fold cross‐validation, we identified key predictors for nomogram development. The model's performance was rigorously evaluated through discrimination (C‐index, AUC‐ROC), calibration, and decision curve analysis (DCA) in both training (70%) and validation (30%) cohorts. Results: Our hemorrhage‐specific nomogram incorporated five independent predictors: (1) age at initial hemorrhage, (2) surgical timing (optimal 3–6 month window post‐ictus), (3) preoperative functional status (modified Rankin Scale), (4) perioperative complications, and (5) recurrent hemorrhage. The model demonstrated excellent discrimination (C‐index: 0.889 training, 0.819 validation) and calibration. DCA confirmed superior clinical utility across 15%–80% probability thresholds compared to conventional approaches. Restricted cubic spline analysis validated the non‐linear relationship between surgical timing and outcomes. Conclusions: This study provides the first validated clinical decision tool for adult hemorrhagic MMD, establishing 3–6 months post‐hemorrhage as the optimal surgical window for EDAS. The nomogram's robust performance metrics and RCS‐validated temporal risk stratification offer neurosurgeons an evidence‐based approach to optimize revascularization timing and improve functional outcomes.
- Open Access
- 1 May 2026
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 69 (3) , 459-471
The Feasibility, Accuracy and Safety of Robot-Assisted Ventriculoperitoneal Shunt
Objective : Ventriculoperitoneal shunt (VPS) treats hydrocephalus effectively, but manual ventricular catheter placement has a high misplacement rate. This study assesses the feasibility, accuracy, and safety of robot-assisted VPS.Methods : A retrospective analysis was performed on the clinical data of 87 patients from 2022 to 2024, with 42 receiving robot-assisted VPS and 45 receiving conventional manual VPS. Logistic regression analysis was performed to identify risk factors affecting placement accuracy.Results : The robot-assisted cohort showed smaller bilateral frontal horn diameters and a lower Evans index (p<0.05). It achieved higher placement accuracy, required fewer puncture attempts, and had a lower postoperative complication rate (p0.05). Logistic regression analysis confirmed robot-assistance as a key factor for accurate catheter placement (odds ratio, 6.52; p<0.001).Conclusion : Robot-assisted VPS achieves precise placement, reduces puncture attempts and complications, and does not increase time costs, confirming its clinical feasibility, accuracy, and safety.
- 1 May 2026
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 69 (3) , 459-471
Open AccessThe Feasibility, Accuracy and Safety of Robot-Assisted Ventriculoperitoneal Shunt
Objective : Ventriculoperitoneal shunt (VPS) treats hydrocephalus effectively, but manual ventricular catheter placement has a high misplacement rate. This study assesses the feasibility, accuracy, and safety of robot-assisted VPS.Methods : A retrospective analysis was performed on the clinical data of 87 patients from 2022 to 2024, with 42 receiving robot-assisted VPS and 45 receiving conventional manual VPS. Logistic regression analysis was performed to identify risk factors affecting placement accuracy.Results : The robot-assisted cohort showed smaller bilateral frontal horn diameters and a lower Evans index (p<0.05). It achieved higher placement accuracy, required fewer puncture attempts, and had a lower postoperative complication rate (p0.05). Logistic regression analysis confirmed robot-assistance as a key factor for accurate catheter placement (odds ratio, 6.52; p<0.001).Conclusion : Robot-assisted VPS achieves precise placement, reduces puncture attempts and complications, and does not increase time costs, confirming its clinical feasibility, accuracy, and safety.
- Open Access
- 17 June 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (12) , e039054
Long‐Term Outcomes in Patients With Hemorrhagic Moyamoya Disease Combined With Hypertension After Encephaloduroarteriosynangiosis
Background: Although hypertension is prevalent in adults with moyamoya disease (MMD) and intracranial hemorrhage significantly worsens prognosis, the impact of hypertension on long‐term outcomes after encephaloduroarteriosynangiosis in hemorrhagic MMD remains unclear; this retrospective cohort study used propensity score matching to compare outcomes between hypertensive and nonhypertensive patients and preliminarily assess the role of blood pressure management. Methods: After propensity score matching, long‐term outcomes post‐ encephaloduroarteriosynangiosis in patients with hemorrhagic MMD with hypertension from January 2010 to December 2018 were analyzed. The clinical and radiological data were collected. Kaplan–Meier curves evaluated the relationship between recurrence‐free survival, overall survival (OS), and hypertension. Univariate and multivariate Cox regression assessed independent factors influencing hematoma recurrence‐free survival and OS. Subgroup analysis of patients with hemorrhagic MMD with hypertension assessed the impact of different blood management on long‐term outcomes. Results: Kaplan–Meier curves showed a significant correlation between hypertension and decreased hematoma recurrence‐free survival ( P =0.004) and OS ( P =0.014) during follow‐up. The 5‐year recurrence‐free survival rate did not significantly differ between hypertensive and nonhypertensive groups ( P =0.77). Hypertension was associated with reduced 10‐year hematoma recurrence‐free survival ( P =0.004) and OS ( P =0.014). In multivariate analysis, hypertension ( P =0.015), perioperative complications ( P =0.003), and choroidal anastomosis ( P =0.0008) significantly influenced hematoma recurrence‐free survival. Analysis of OS revealed significant differences for hypertension ( P =0.018), follow‐up duration ( P P =0.041), and initial mRS ( P P =0.049) but did not improve OS ( P =0.31). Conclusions: This study highlights significant differences in hematoma recurrence‐free survival and OS between patients with hemorrhagic MMD with and without hypertension. A subgroup analysis of those with hypertension showed that optimal blood pressure control notably lowered hematoma recurrence but did not improve OS. For patients with hemorrhagic MMD with hypertension, optimizing blood pressure alone may be insufficient, emphasizing the importance of personalized integrated strategies for this patient subgroup.
- 17 June 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (12) , e039054
Open AccessLong‐Term Outcomes in Patients With Hemorrhagic Moyamoya Disease Combined With Hypertension After Encephaloduroarteriosynangiosis
Background: Although hypertension is prevalent in adults with moyamoya disease (MMD) and intracranial hemorrhage significantly worsens prognosis, the impact of hypertension on long‐term outcomes after encephaloduroarteriosynangiosis in hemorrhagic MMD remains unclear; this retrospective cohort study used propensity score matching to compare outcomes between hypertensive and nonhypertensive patients and preliminarily assess the role of blood pressure management. Methods: After propensity score matching, long‐term outcomes post‐ encephaloduroarteriosynangiosis in patients with hemorrhagic MMD with hypertension from January 2010 to December 2018 were analyzed. The clinical and radiological data were collected. Kaplan–Meier curves evaluated the relationship between recurrence‐free survival, overall survival (OS), and hypertension. Univariate and multivariate Cox regression assessed independent factors influencing hematoma recurrence‐free survival and OS. Subgroup analysis of patients with hemorrhagic MMD with hypertension assessed the impact of different blood management on long‐term outcomes. Results: Kaplan–Meier curves showed a significant correlation between hypertension and decreased hematoma recurrence‐free survival ( P =0.004) and OS ( P =0.014) during follow‐up. The 5‐year recurrence‐free survival rate did not significantly differ between hypertensive and nonhypertensive groups ( P =0.77). Hypertension was associated with reduced 10‐year hematoma recurrence‐free survival ( P =0.004) and OS ( P =0.014). In multivariate analysis, hypertension ( P =0.015), perioperative complications ( P =0.003), and choroidal anastomosis ( P =0.0008) significantly influenced hematoma recurrence‐free survival. Analysis of OS revealed significant differences for hypertension ( P =0.018), follow‐up duration ( P P =0.041), and initial mRS ( P P =0.049) but did not improve OS ( P =0.31). Conclusions: This study highlights significant differences in hematoma recurrence‐free survival and OS between patients with hemorrhagic MMD with and without hypertension. A subgroup analysis of those with hypertension showed that optimal blood pressure control notably lowered hematoma recurrence but did not improve OS. For patients with hemorrhagic MMD with hypertension, optimizing blood pressure alone may be insufficient, emphasizing the importance of personalized integrated strategies for this patient subgroup.
- Open Access
- 12 June 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (9) , 5821-5833
Preoperative hemorrhagic risk stratification in pediatric moyamoya disease: a multi-institutional propensity score-matched analysis
Background: Pediatric hemorrhagic moyamoya disease (MMD) is rare, and currently, no risk model exists for predicting preoperative bleeding. We aimed to develop a nomogram to predict the preoperative bleeding risk in children with MMD. Methods: We retrospectively analyzed data from 1350 children diagnosed with MMD from January 2004 to December 2022 at our institution. After applying propensity score matching (PSM), 392 patients were selected for analysis, comprising 98 with hemorrhagic MMD and 294 with non-hemorrhagic MMD. The cohort was divided into training and internal validation cohorts. To construct the nomogram, variable selection was performed using the least absolute shrinkage and selection operator (LASSO), and the model was externally validated with an independent cohort of 70 children. We utilized multivariate logistic regression to determine odds ratios and 95% confidence intervals for preoperative bleeding risk. A predictive nomogram was then developed from the logistic model, with polynomial equations to quantify risk. The model’s effectiveness was evaluated using receiver operating characteristic curves, calibration plots, and decision curve analyses (DCAs). Inflection points for continuous variables were identified using restricted cubic spline (RCS) analysis. Results: The LASSO model demonstrated superior discriminative performance compared to six alternative models, achieving area under the curve values of 91.5% in the training cohort, 78.4% in the internal validation cohort, and 91.2% in the external validation cohort. Based on variables selected through the LASSO model, we developed a nomogram incorporating three critical factors: age at onset ( P = 0.001), anterior choroidal artery grades 1 ( P = 0.047) and 2 ( P < 0.001), and posterior communicating artery grades 1 ( P = 0.002) and 2 ( P = 0.032). Calibration plots indicated strong concordance between predicted and observed outcomes across both training and validation cohorts (Hosmer–Lemeshow P = 0.503), affirming the model’s accuracy. Additionally, DCA highlighted the nomogram’s clinical utility by effectively identifying patients at high risk. RCS analysis revealed age 8 as a pivotal inflection point ( P < 0.05), marking a significant increase in the risk of preoperative bleeding beyond this age. Conclusion: The nomogram demonstrated high accuracy in predicting preoperative bleeding risk in pediatric patients with MMD. This predictive accuracy may enhance preoperative evaluation by surgeons, allowing for more proactive intervention and intensified monitoring of children at elevated risk of bleeding, thereby improving patient outcomes.
- 12 June 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (9) , 5821-5833
Open AccessPreoperative hemorrhagic risk stratification in pediatric moyamoya disease: a multi-institutional propensity score-matched analysis
Background: Pediatric hemorrhagic moyamoya disease (MMD) is rare, and currently, no risk model exists for predicting preoperative bleeding. We aimed to develop a nomogram to predict the preoperative bleeding risk in children with MMD. Methods: We retrospectively analyzed data from 1350 children diagnosed with MMD from January 2004 to December 2022 at our institution. After applying propensity score matching (PSM), 392 patients were selected for analysis, comprising 98 with hemorrhagic MMD and 294 with non-hemorrhagic MMD. The cohort was divided into training and internal validation cohorts. To construct the nomogram, variable selection was performed using the least absolute shrinkage and selection operator (LASSO), and the model was externally validated with an independent cohort of 70 children. We utilized multivariate logistic regression to determine odds ratios and 95% confidence intervals for preoperative bleeding risk. A predictive nomogram was then developed from the logistic model, with polynomial equations to quantify risk. The model’s effectiveness was evaluated using receiver operating characteristic curves, calibration plots, and decision curve analyses (DCAs). Inflection points for continuous variables were identified using restricted cubic spline (RCS) analysis. Results: The LASSO model demonstrated superior discriminative performance compared to six alternative models, achieving area under the curve values of 91.5% in the training cohort, 78.4% in the internal validation cohort, and 91.2% in the external validation cohort. Based on variables selected through the LASSO model, we developed a nomogram incorporating three critical factors: age at onset ( P = 0.001), anterior choroidal artery grades 1 ( P = 0.047) and 2 ( P < 0.001), and posterior communicating artery grades 1 ( P = 0.002) and 2 ( P = 0.032). Calibration plots indicated strong concordance between predicted and observed outcomes across both training and validation cohorts (Hosmer–Lemeshow P = 0.503), affirming the model’s accuracy. Additionally, DCA highlighted the nomogram’s clinical utility by effectively identifying patients at high risk. RCS analysis revealed age 8 as a pivotal inflection point ( P < 0.05), marking a significant increase in the risk of preoperative bleeding beyond this age. Conclusion: The nomogram demonstrated high accuracy in predicting preoperative bleeding risk in pediatric patients with MMD. This predictive accuracy may enhance preoperative evaluation by surgeons, allowing for more proactive intervention and intensified monitoring of children at elevated risk of bleeding, thereby improving patient outcomes.
- Open Access
- 12 May 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (5) , e70180
Global, Regional, and National Burden of Stroke on Children and Adolescents Aged Under 20 Years From 1990 to 2021, With Projections of Disability‐Adjusted Life Year to 2050: A Comprehensive Demographic Analysis for the Global Burden of Disease Study 2021
Background: Stroke in children is a global epidemic.Methods: Data on stroke, including incidence, DALYs, mortality, and associated risk factors from 1990 to 2021, were obtained from the Global Burden of Disease (GBD) study, 2021. Estimated annual percentage changes were calculated to evaluate changes in the age‐standardized rates of incidence (ASIR), DALYs (ASDR), and mortality (ASMR), as well as trends by age, sex, and sociodemographic index (SDI). Projections of DALYs to 2050 were made.Results: In 2021, there were 310,133 incident stroke cases, accounting for 24,807 deaths and 2,414,655 DALYs among children and adolescents. The global ASIR, ASDR, and ASMR for stroke were 11.8, 93.9, and 1.0 per 100,000 population, respectively. Middle‐to‐low‐SDI regions accounted for 81.6% of incident cases, 90.2% of DALYs, and 92.7% of deaths. A reversed V‐shaped association was observed between SDI and ASRs. Children < 1 year had the highest ASRs, with rates generally decreasing with age, and the highest incidence of hemorrhagic stroke. Adolescents aged 15–19 years had the highest incidence of ischemic stroke. Non‐optimal temperature contributed the most to the DALYs and death rates for stroke. By 2050, it is projected that 282,404 DALYs will be lost due to stroke.Conclusions: Stroke burden varies by the GBD region, country, age, sex, and SDI. Despite declines in ASRs, stroke remains a significant burden, especially in middle‐to‐low‐SDI regions, among children < 1 year, and among those with intracerebral hemorrhage. Non‐optimal temperature emerges as the leading modifiable risk factor for children stroke; targeted interventions can prevent this.
- 12 May 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (5) , e70180
Open AccessGlobal, Regional, and National Burden of Stroke on Children and Adolescents Aged Under 20 Years From 1990 to 2021, With Projections of Disability‐Adjusted Life Year to 2050: A Comprehensive Demographic Analysis for the Global Burden of Disease Study 2021
Background: Stroke in children is a global epidemic.Methods: Data on stroke, including incidence, DALYs, mortality, and associated risk factors from 1990 to 2021, were obtained from the Global Burden of Disease (GBD) study, 2021. Estimated annual percentage changes were calculated to evaluate changes in the age‐standardized rates of incidence (ASIR), DALYs (ASDR), and mortality (ASMR), as well as trends by age, sex, and sociodemographic index (SDI). Projections of DALYs to 2050 were made.Results: In 2021, there were 310,133 incident stroke cases, accounting for 24,807 deaths and 2,414,655 DALYs among children and adolescents. The global ASIR, ASDR, and ASMR for stroke were 11.8, 93.9, and 1.0 per 100,000 population, respectively. Middle‐to‐low‐SDI regions accounted for 81.6% of incident cases, 90.2% of DALYs, and 92.7% of deaths. A reversed V‐shaped association was observed between SDI and ASRs. Children < 1 year had the highest ASRs, with rates generally decreasing with age, and the highest incidence of hemorrhagic stroke. Adolescents aged 15–19 years had the highest incidence of ischemic stroke. Non‐optimal temperature contributed the most to the DALYs and death rates for stroke. By 2050, it is projected that 282,404 DALYs will be lost due to stroke.Conclusions: Stroke burden varies by the GBD region, country, age, sex, and SDI. Despite declines in ASRs, stroke remains a significant burden, especially in middle‐to‐low‐SDI regions, among children < 1 year, and among those with intracerebral hemorrhage. Non‐optimal temperature emerges as the leading modifiable risk factor for children stroke; targeted interventions can prevent this.
- Open Access
- 29 April 2025
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 22 (1) , 1-20
Multi-omic serum analysis reveals ferroptosis pathways and diagnostic molecular signatures associated with Moyamoya diseases
Moyamoya disease (MMD) is a rare cerebrovascular disease in humans. Although early revascularization can improve symptoms, it cannot reverse the progression of the disease. The current diagnosis still relies on traditional a Digital Subtraction Angiography (DSA) examination, which is invasive and expensive, leading to delayed diagnosis and affecting treatment timing and patient prognosis. The ability to diagnose MMD early and develop personalized treatment plans can significantly improve the prognosis of patients. Here, we have introduced the research on MMD biomarkers. By integrating proteomics and metabolomics data, we have successfully identified over 1700 features from more than 60 serum samples collected at the onset of symptoms in MMD patients. We use multiple computational strategies to interpret complex information in serum, providing a comprehensive perspective for early diagnosis of MMD. Diagnostic ability of our biomarker is significantly better than previous studies, especially when used in combination. In the study of molecular mechanisms, we found that the ferroptosis pathway was significant disruption in MMD patients, which was also confirmed by transcriptomics data. Finally, we validated the metabolites and proteins associated with ferroptosis pathways, as well as the biomarkers screened by machine learning, using another independent MMD cohort. Our research provides important clues for the diagnosis of MMD, and this assay can identify MMD early, thereby promoting stronger monitoring and intervention.
- 29 April 2025
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 22 (1) , 1-20
Open AccessMulti-omic serum analysis reveals ferroptosis pathways and diagnostic molecular signatures associated with Moyamoya diseases
Moyamoya disease (MMD) is a rare cerebrovascular disease in humans. Although early revascularization can improve symptoms, it cannot reverse the progression of the disease. The current diagnosis still relies on traditional a Digital Subtraction Angiography (DSA) examination, which is invasive and expensive, leading to delayed diagnosis and affecting treatment timing and patient prognosis. The ability to diagnose MMD early and develop personalized treatment plans can significantly improve the prognosis of patients. Here, we have introduced the research on MMD biomarkers. By integrating proteomics and metabolomics data, we have successfully identified over 1700 features from more than 60 serum samples collected at the onset of symptoms in MMD patients. We use multiple computational strategies to interpret complex information in serum, providing a comprehensive perspective for early diagnosis of MMD. Diagnostic ability of our biomarker is significantly better than previous studies, especially when used in combination. In the study of molecular mechanisms, we found that the ferroptosis pathway was significant disruption in MMD patients, which was also confirmed by transcriptomics data. Finally, we validated the metabolites and proteins associated with ferroptosis pathways, as well as the biomarkers screened by machine learning, using another independent MMD cohort. Our research provides important clues for the diagnosis of MMD, and this assay can identify MMD early, thereby promoting stronger monitoring and intervention.
- Open Access
- 9 December 2024
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (12) , e70165
Comparing Outcomes of Moyamoya Disease and Moyamoya Syndrome in a Real‐World Scenario: A Cohort Study
Background: Moyamoya disease (MMD) and moyamoya syndrome (MMS) are rare cerebrovascular conditions with unclear distinctions in clinical presentation and prognosis.Aim: This study assessed potential differences between MMD and MMS patients using real‐world data on clinical manifestations, surgical outcomes, and stroke risk factors.Methods: This multicenter, retrospective cohort study examined patients with MMD or MMS treated at three tertiary academic hospitals in China, with a mean follow‐up of 11.2 ± 3.1 years. Clinical differences were compared between MMD and MMS, and postoperative cerebrovascular events were compared between patients who underwent surgery and those with conservative management. Primary outcomes were postoperative ischemic and hemorrhagic strokes. Risk factors were evaluated via multivariate Cox regression analysis.Results: Of the 2565 patients, 2349 had MMD and 216 had MMS. After 1:1 propensity‐score matching, no significant differences were observed between these two cohorts. Surgical patients had fewer cerebrovascular events than those who received conservative treatment (HR, 0.487; 95% CI, 0.334–0.711; p < 0.001). Preadmission modified Rankin scale scores > 2 (HR, 3.139; 95% CI, 1.254–7.857; p = 0.015) and periprocedural complications (HR, 8.666; 95% CI, 3.476–21.604; p < 0.001) were independent stroke risk factors in patients with MMD. Periprocedural complications (HR, 31.807; 95% CI, 10.916–92.684; p < 0.001) increased stroke risk in patients with MMS.Conclusions: This real‐world study revealed substantial clinical overlap between MMD and MMS. Both groups derived significant benefits from surgical revascularization, suggesting distinction may not be necessary to guide surgical management decisions. Optimizing preoperative status and preventing periprocedural complications may improve outcomes in these rare cerebrovascular conditions.Trial Registration: This study has been registered in the Chinese Clinical trial registry (registration number: ChiCTR2200064160)
- 9 December 2024
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (12) , e70165
Open AccessComparing Outcomes of Moyamoya Disease and Moyamoya Syndrome in a Real‐World Scenario: A Cohort Study
Background: Moyamoya disease (MMD) and moyamoya syndrome (MMS) are rare cerebrovascular conditions with unclear distinctions in clinical presentation and prognosis.Aim: This study assessed potential differences between MMD and MMS patients using real‐world data on clinical manifestations, surgical outcomes, and stroke risk factors.Methods: This multicenter, retrospective cohort study examined patients with MMD or MMS treated at three tertiary academic hospitals in China, with a mean follow‐up of 11.2 ± 3.1 years. Clinical differences were compared between MMD and MMS, and postoperative cerebrovascular events were compared between patients who underwent surgery and those with conservative management. Primary outcomes were postoperative ischemic and hemorrhagic strokes. Risk factors were evaluated via multivariate Cox regression analysis.Results: Of the 2565 patients, 2349 had MMD and 216 had MMS. After 1:1 propensity‐score matching, no significant differences were observed between these two cohorts. Surgical patients had fewer cerebrovascular events than those who received conservative treatment (HR, 0.487; 95% CI, 0.334–0.711; p < 0.001). Preadmission modified Rankin scale scores > 2 (HR, 3.139; 95% CI, 1.254–7.857; p = 0.015) and periprocedural complications (HR, 8.666; 95% CI, 3.476–21.604; p < 0.001) were independent stroke risk factors in patients with MMD. Periprocedural complications (HR, 31.807; 95% CI, 10.916–92.684; p < 0.001) increased stroke risk in patients with MMS.Conclusions: This real‐world study revealed substantial clinical overlap between MMD and MMS. Both groups derived significant benefits from surgical revascularization, suggesting distinction may not be necessary to guide surgical management decisions. Optimizing preoperative status and preventing periprocedural complications may improve outcomes in these rare cerebrovascular conditions.Trial Registration: This study has been registered in the Chinese Clinical trial registry (registration number: ChiCTR2200064160)
- Open Access
- 3 September 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1456392
Exploring the transcriptomic landscape of moyamoya disease and systemic lupus erythematosus: insights into crosstalk genes and immune relationships
Background: Systemic Lupus Erythematosus (SLE) is acknowledged for its significant influence on systemic health. This study sought to explore potential crosstalk genes, pathways, and immune cells in the relationship between SLE and moyamoya disease (MMD).Methods: We obtained data on SLE and MMD from the Gene Expression Omnibus (GEO) database. Differential expression analysis and weighted gene co-expression network analysis (WGCNA) were conducted to identify common genes. Subsequently, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed on these shared genes. Hub genes were further selected through the least absolute shrinkage and selection operator (LASSO) regression, and a receiver operating characteristic (ROC) curve was generated based on the results of this selection. Finally, single-sample Gene Set Enrichment Analysis (ssGSEA) was utilized to assess the infiltration levels of 28 immune cells in the expression profile and their association with the identified hub genes.Results: By intersecting the important module genes from WGCNA with the DEGs, the study highlighted CAMP, CFD, MYO1F, CTSS, DEFA3, NLRP12, MAN2B1, NMI, QPCT, KCNJ2, JAML, MPZL3, NDC80, FRAT2, THEMIS2, CCL4, FCER1A, EVI2B, CD74, HLA-DRB5, TOR4A, GAPT, CXCR1, LAG3, CD68, NCKAP1L, TMEM33, and S100P as key crosstalk genes linking SLE and MMD. GO analysis indicated that these shared genes were predominantly enriched in immune system process and immune response. LASSO analysis identified MPZL3 as the optimal shared diagnostic biomarkers for both SLE and MMD. Additionally, the analysis of immune cell infiltration revealed the significant involvement of activation of T and monocytes cells in the pathogenesis of SLE and MMD.Conclusion: This study is pioneering in its use of bioinformatics tools to explore the close genetic relationship between MMD and SLE. The genes CAMP, CFD, MYO1F, CTSS, DEFA3, NLRP12, MAN2B1, NMI, QPCT, KCNJ2, JAML, MPZL3, NDC80, FRAT2, THEMIS2, CCL4, FCER1A, EVI2B, CD74, HLA-DRB5, TOR4A, GAPT, CXCR1, LAG3, CD68, NCKAP1L, TMEM33, and S100P have been identified as key crosstalk genes that connect MMD and SLE. Activation of T and monocytes cells-mediated immune responses are proposed to play a significant role in the association between MMD and SLE.
- 3 September 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1456392
Open AccessExploring the transcriptomic landscape of moyamoya disease and systemic lupus erythematosus: insights into crosstalk genes and immune relationships
Background: Systemic Lupus Erythematosus (SLE) is acknowledged for its significant influence on systemic health. This study sought to explore potential crosstalk genes, pathways, and immune cells in the relationship between SLE and moyamoya disease (MMD).Methods: We obtained data on SLE and MMD from the Gene Expression Omnibus (GEO) database. Differential expression analysis and weighted gene co-expression network analysis (WGCNA) were conducted to identify common genes. Subsequently, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed on these shared genes. Hub genes were further selected through the least absolute shrinkage and selection operator (LASSO) regression, and a receiver operating characteristic (ROC) curve was generated based on the results of this selection. Finally, single-sample Gene Set Enrichment Analysis (ssGSEA) was utilized to assess the infiltration levels of 28 immune cells in the expression profile and their association with the identified hub genes.Results: By intersecting the important module genes from WGCNA with the DEGs, the study highlighted CAMP, CFD, MYO1F, CTSS, DEFA3, NLRP12, MAN2B1, NMI, QPCT, KCNJ2, JAML, MPZL3, NDC80, FRAT2, THEMIS2, CCL4, FCER1A, EVI2B, CD74, HLA-DRB5, TOR4A, GAPT, CXCR1, LAG3, CD68, NCKAP1L, TMEM33, and S100P as key crosstalk genes linking SLE and MMD. GO analysis indicated that these shared genes were predominantly enriched in immune system process and immune response. LASSO analysis identified MPZL3 as the optimal shared diagnostic biomarkers for both SLE and MMD. Additionally, the analysis of immune cell infiltration revealed the significant involvement of activation of T and monocytes cells in the pathogenesis of SLE and MMD.Conclusion: This study is pioneering in its use of bioinformatics tools to explore the close genetic relationship between MMD and SLE. The genes CAMP, CFD, MYO1F, CTSS, DEFA3, NLRP12, MAN2B1, NMI, QPCT, KCNJ2, JAML, MPZL3, NDC80, FRAT2, THEMIS2, CCL4, FCER1A, EVI2B, CD74, HLA-DRB5, TOR4A, GAPT, CXCR1, LAG3, CD68, NCKAP1L, TMEM33, and S100P have been identified as key crosstalk genes that connect MMD and SLE. Activation of T and monocytes cells-mediated immune responses are proposed to play a significant role in the association between MMD and SLE.
- Open Access
- 1 September 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 6173-6192
Comprehensive Serum Proteomic and Metabolomic Profiles of Pediatric Patients with Moyamoya Disease Reveal Core Pathways
Background: Moyamoya disease (MMD) signifies a cerebrovascular disorder with obscure origin and a more rapid and severe progression in children than adults. This investigation aims to uncover age-associated distinctions through proteomic and metabolomic profiling to gain insights into the underlying mechanisms of MMD. Methods: Twelve MMD patients—six children and six adults—along with six healthy controls (HC), participated, each providing a 10 mL blood sample. Serum proteomic and metabolomic analyses were conducted using ultra-performance liquid chromatography and high-resolution mass spectrometry, complemented by bioinformatics to identify differential biomolecules and their interactions. Pathway implications were ascertained using GO and KEGG enrichment analysis. Results: Notable proteomic and metabolomic discrepancies were observed between pediatric and adult MMD subjects. A total of 235 and 216 proteins varied in adult and pediatric cases compared to HCs, with 73 proteins shared. In addition, 129 and 74 anionic, plus 96 and 104 cationic metabolites, were differentially expressed in the pediatric and adult groups, respectively, with 34 anionic and 28 cationic metabolites in common. Age-specific biomolecules further characterized these distinctions. Enrichment analysis pinpointed immunity and inflammation pathways, with vitamin digestion and absorption highlighted as pivotal in pediatric MMD. Conclusion: This study unveils distinct metabolic and proteomic patterns within pediatric and adult MMD patients. The critical role of the vitamin digestion and absorption pathway in the pathogenesis of pediatric MMD offers novel insight into disease mechanisms.
- 1 September 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 6173-6192
Open AccessComprehensive Serum Proteomic and Metabolomic Profiles of Pediatric Patients with Moyamoya Disease Reveal Core Pathways
Background: Moyamoya disease (MMD) signifies a cerebrovascular disorder with obscure origin and a more rapid and severe progression in children than adults. This investigation aims to uncover age-associated distinctions through proteomic and metabolomic profiling to gain insights into the underlying mechanisms of MMD. Methods: Twelve MMD patients—six children and six adults—along with six healthy controls (HC), participated, each providing a 10 mL blood sample. Serum proteomic and metabolomic analyses were conducted using ultra-performance liquid chromatography and high-resolution mass spectrometry, complemented by bioinformatics to identify differential biomolecules and their interactions. Pathway implications were ascertained using GO and KEGG enrichment analysis. Results: Notable proteomic and metabolomic discrepancies were observed between pediatric and adult MMD subjects. A total of 235 and 216 proteins varied in adult and pediatric cases compared to HCs, with 73 proteins shared. In addition, 129 and 74 anionic, plus 96 and 104 cationic metabolites, were differentially expressed in the pediatric and adult groups, respectively, with 34 anionic and 28 cationic metabolites in common. Age-specific biomolecules further characterized these distinctions. Enrichment analysis pinpointed immunity and inflammation pathways, with vitamin digestion and absorption highlighted as pivotal in pediatric MMD. Conclusion: This study unveils distinct metabolic and proteomic patterns within pediatric and adult MMD patients. The critical role of the vitamin digestion and absorption pathway in the pathogenesis of pediatric MMD offers novel insight into disease mechanisms.